表紙
市場調查報告書

市場焦點:注意力不足過動症(ADHD)

Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)

出版商 Datamonitor Healthcare 商品編碼 573558
出版日期 內容資訊 英文 56 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
市場焦點:注意力不足過動症(ADHD) Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)
出版日期: 2019年10月25日內容資訊: 英文 56 Pages
簡介

本報告提供ADHD (過動症)的治療藥市場相關分析,提供疾病概要和患者數的轉變·預測,目前的主要治療方法,ADHD治療藥市場趨勢預測 (今後10年份),資本交易的動向,目前開發中的臨床實驗進展等調查。

分析的要點

疾病的背景情況

  • ADHD詳細分類

治療方法

  • 非藥物治療
  • 藥物治療

流行病學

開發平台上的醫藥品

已上市醫藥品

  • 各國的認證情形

今後主要的動向

授權合約·資產收購交易

母專利

商機

臨床實驗形勢

  • 贊助商一覽:各狀態
  • 贊助商一覽:各期
  • 近幾年趨勢

相關分析

  • 處方藥的資訊

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0178813

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD)​ market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were 177.3 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 187.4 million prevalent cases by

2026. Approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and the alpha 2 adrenergic receptor. The vast majority of approved therapies are administered via the oral route.

The largest proportion of industry-sponsored drugs in active clinical development for ADHD are in Phase III. Therapies in mid-to-late-stage development for ADHD focus on a wide variety of targets. The majority of pipeline drugs in midto-late-stage development are administered via the oral route, with only one drug also being tested in intramuscular and subcutaneous formulations.

High-impact upcoming events for drugs in the ADHD space comprise topline Phase III trial results, pivotal efficacy study results, an expected patent expiration, and a meeting with the FDA.

The overall likelihood of approval of a Phase I ADHD asset is 12.9%, and the average probability a drug advances from Phase III is 78.6%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 8.8 years in the overall psychiatry space.

There have been 21 licensing and asset acquisition deals involving ADHD drugs during 2014-19. Impax Laboratories' acquisition of certain assets related to generic products from Teva and Allergan in 2016 for $586m was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for ADHD have been in the late phases of development, with 54% in Phase III-IV, and 46% in Phase I-II.

The US has a substantial lead in the number of ADHD clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the ADHD space is dominated by completed trials. Takeda has the highest number of completed clinical trials for ADHD, with 157 trials.

Takeda leads the industry sponsors with the highest number of clinical trials for ADHD, followed by Eli Lilly and Johnson & Johnson

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Non-pharmacological therapy
  • Pharmacological therapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Multiple Drugs for ADHD (September 04, 2019)
  • Vafidemstat for ADHD (April 25, 2019)
  • Monarch eTNS system for ADHD (April 19, 2019)
  • SPN-812 for ADHD (March 28, 2019)
  • AEVI-001 for ADHD (January 02, 2019)
  • SPN-812 for ADHD (December 20, 2018)
  • SPN-812 for ADHD (December 06, 2018)
  • Dasotraline for ADHD (August 31, 2018)
  • KP415 for ADHD (July 9, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • NeuroSigma Monarch eTNS Becomes The First FDA-Cleared ADHD Device
  • Approval of Vyvanse for Pediatric ADHD in Japan
  • Adhansia XR Approval Boosts Purdue's Move Away From Opioids

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • KemPharm Offloads Two ADHD Candidates To Gurnet Point
  • Shionogi Licenses Akili's Digital Medicine Candidates For ADHD, ASD

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of ADHD, 2017-26
  • Figure 2: Overview of pipeline drugs for ADHD in the US
  • Figure 3: Pipeline drugs for ADHD, by company
  • Figure 4: Pipeline drugs for ADHD, by drug type
  • Figure 5: Pipeline drugs for ADHD, by classification
  • Figure 6: Vafidemstat for ADHD (April 25, 2019): Phase IIa - REIMAGINE (Spain)
  • Figure 7: SPN-812 for ADHD (March 28, 2019): Phase III - P304 (High Dose Adolescents)
  • Figure 8: AEVI-001 for ADHD (January 02, 2019): Phase II - ASCEND Part A (w/ mGluR Mutations Ages 6-17 Years), Phase II - ASCEND Part B (w/o mGluR Mutations, Ages 6 to 17 Years)
  • Figure 9: SPN-812 for ADHD (December 20, 2018): Phase III - P302 (Low Dose Adolescents)
  • Figure 10: SPN-812 for ADHD (December 06, 2018): Phase III - P301 (Low Dose Children), Phase III - P303 (High Dose Children)
  • Figure 11: KP415 for ADHD (July 9, 2018): Phase III - Children (KP415.E01)
  • Figure 12: Key upcoming events in ADHD
  • Figure 13: Probability of success in the ADHD pipeline
  • Figure 14: Licensing and asset acquisition deals in ADHD, 2014-19
  • Figure 15: Parent patents in ADHD
  • Figure 16: Clinical trials in ADHD
  • Figure 17: Top 10 drugs for clinical trials in ADHD
  • Figure 18: Top 10 companies for clinical trials in ADHD
  • Figure 19: Trial locations in ADHD
  • Figure 20: ADHD trials status
  • Figure 21: ADHD trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of ADHD, 2017-26
  • Table 2: Marketed drugs for ADHD
  • Table 3: Pipeline drugs for ADHD in the US
  • Table 4: Multiple Drugs for ADHD (September 04, 2019)
  • Table 5: Vafidemstat for ADHD (April 25, 2019)
  • Table 6: Monarch eTNS system for ADHD (April 19, 2019)
  • Table 7: SPN-812 for ADHD (March 28, 2019)
  • Table 8: AEVI-001 for ADHD (January 02, 2019)
  • Table 9: SPN-812 for ADHD (December 20, 2018)
  • Table 10: SPN-812 for ADHD (December 06, 2018)
  • Table 11: Dasotraline for ADHD (August 31, 2018)
  • Table 12: KP415 for ADHD (July 9, 2018)
  • Table 13: Historical global sales, by drug ($m), 2014-18
  • Table 14: Forecasted global sales, by drug ($m), 2019-23
Back to Top